Story

Neuronetics Stock Surges on Q2 Earnings Beat, Progress Toward Profitability

ENTHMSVIIDZHZH-TWJAKOHI
Aug 11, 20261 min read
Neuronetics Stock Surges on Q2 Earnings Beat, Progress Toward Profitability
Text size
Background

Neuronetics Inc. (NASDAQ: STIM) stock surged in pre-market trading Tuesday after the company announced second-quarter 2026 financial results that decisively beat analyst expectations, signaling that its turnaround strategy is gaining traction.

Earnings Beat Drives Rally

The medical device company reported a significant improvement on its bottom line, posting a net loss that was much narrower than anticipated. The strong performance was driven by solid revenue growth and operational progress.

Key figures from the second-quarter report include:

  • Total Revenue: $41.6 million, an increase of 9.1% compared to the same period in 2025.
  • Net Loss Per Share: -$0.05, a substantial improvement from a loss of -$0.15 per share in Q2 2025 and well ahead of the consensus analyst estimate of a -$0.12 loss per share.
  • Adjusted EBITDA: $0.3 million, a positive turn from a loss of $5.6 million in the year-ago period.

Operational Momentum

Sample IUX Markets – In-articleAd

Growth was primarily fueled by the company's Greenbrook clinic segment, which saw revenue climb 16.8% year-over-year to $26.9 million. Neuronetics also demonstrated improved financial discipline, reducing its net cash used in operations and investing to $1.4 million, down from $3.8 million in the second quarter of 2025.

CEO Dan Reuvers called the period "a quarter of real operational progress, and meaningful steps toward our goal of sustained profitability and positive net cash flow from operations and investing." The company also announced several new executive appointments, including a new CFO, which may have further bolstered investor confidence.

Market Reaction

Investors reacted positively to the combination of a significant earnings beat, accelerating clinic revenue, and a sharp reduction in cash burn. The stock jumped 24% in pre-open trading, according to Investing.com. The move was specific to Neuronetics, as the broader market saw only modest gains and no material news was released by key competitors.

Read next

More on Stocks
Back to latest news

LATEST